Five Boards Authorize $3.6B in Buybacks Inside 72 Hours Across Disparate Sectors

Cosmos Health, Yiren Digital, Streamex, ArcelorMittal, and Strategy announced or expanded share repurchase programs within the same 72-hour window, aggregating roughly $3.6 billion in authorized capital returns. The cluster spans pharmaceutical distribution, Chinese consumer lending, digital media infrastructure, European steel production, and institutional strategy advisory—sectors with no operational overlap and minimal correlation in their capital cycles.

ArcelorMittal accounts for the majority at approximately $2.5 billion, consistent with cyclical steel producers buying equity during margin compression to signal trough confidence. Yiren Digital authorized $600 million, its third program expansion in eighteen months as regulatory clarity returns to Chinese fintech balance sheets. Cosmos Health, a micro-cap pharmaceutical distributor, increased its existing authorization by $183,000—a rounding error in absolute terms but a 40% increase relative to market cap, suggesting insider conviction at sub-book valuations. Streamex and Strategy disclosed smaller authorizations in the $200-400 million range, both tied to recent equity underperformance rather than operational distress.

The simultaneity matters because it reflects board-level re-rating of equity cost of capital across unrelated geographies and business models. Buyback clustering typically precedes market bottoms by 60-90 days when boards act on private information about demand stabilization or input cost deflation not yet visible in public filings. ArcelorMittal's authorization follows three consecutive quarters of declining EBITDA but stable free cash flow, a pattern that historically marks the end of destocking cycles in heavy industry. Yiren's move comes as Chinese household credit demand shows the first sequential improvement since Q2 2023, with 90-day delinquencies down 140 basis points year-over-year. The cross-sector nature removes the narrative risk that one industry is simply returning stranded cash—it suggests multiple boards independently concluded that equity is mispriced relative to forward earnings.

This is not blanket optimism. It is valuation opportunism at a specific moment when public market pricing has divorced from private asset values. Cosmos Health trades at 0.6x tangible book, Yiren at 0.4x, and ArcelorMittal at 0.5x replacement cost for its European mill network. Buybacks at these multiples are accretive even if revenue growth stalls, which is the implicit message: we do not need a recovery to justify current equity prices. Allocators should note that none of these authorizations are time-limited, meaning boards are signaling multi-quarter conviction rather than one-time opportunism. The capital is approved but not yet deployed, creating a technical bid that persists regardless of index flows.

Watch for Q1 2025 10-Q filings to confirm actual share retirements versus authorization theater. ArcelorMittal's February 13 earnings call will clarify whether the program is front-loaded or ratably deployed. Yiren's January regulatory filings with the SEC should show whether the authorization includes accelerated share repurchase agreements, which would indicate urgency. Cosmos Health's daily volume is under 50,000 shares; any material buying will surface immediately in price action. If three or more of these programs show execution rates above 60% by mid-Q1, it confirms boards are buying into weakness rather than signaling strength.

The authorization wave is not macro commentary. It is five independent boards concluding that their stock is the highest-return use of marginal cash.